Neumora Therapeutics, Common Stock Cash Flow From Operations
| NMRA Stock | 9.80 0.14 1.41% |
Neumora Therapeutics, Common fundamentals help investors to digest information that contributes to Neumora Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Neumora Stock. The fundamental analysis module provides a way to measure Neumora Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neumora Therapeutics, stock.
Neumora | Cash Flow From Operations |
Neumora Therapeutics, Common Company Cash Flow From Operations Analysis
Neumora Therapeutics,'s Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Neumora Therapeutics, Cash Flow From Operations | (163.28 M) |
Most of Neumora Therapeutics,'s fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neumora Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Neumora Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Neumora Therapeutics, is extremely important. It helps to project a fair market value of Neumora Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Neumora Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neumora Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neumora Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Neumora Therapeutics, Common has (163.28 Million) in Cash Flow From Operations. This is 130.97% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 116.81% higher than that of the company.
Neumora Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neumora Therapeutics,'s direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neumora Therapeutics, could also be used in its relative valuation, which is a method of valuing Neumora Therapeutics, by comparing valuation metrics of similar companies.Neumora Therapeutics, is currently under evaluation in cash flow from operations category among its peers.
Neumora Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neumora Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neumora Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Neumora Fundamentals
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 1.27 B | ||||
| Shares Outstanding | 161.56 M | ||||
| Shares Owned By Insiders | 27.72 % | ||||
| Shares Owned By Institutions | 64.18 % | ||||
| Number Of Shares Shorted | 9.81 M | ||||
| Price To Book | 5.01 X | ||||
| EBITDA | (187.53 M) | ||||
| Net Income | (235.93 M) | ||||
| Total Debt | 5.23 M | ||||
| Book Value Per Share | 2.38 X | ||||
| Cash Flow From Operations | (163.28 M) | ||||
| Short Ratio | 7.31 X | ||||
| Earnings Per Share | (1.20) X | ||||
| Target Price | 23.33 | ||||
| Number Of Employees | 124 | ||||
| Market Capitalization | 1.61 B | ||||
| Total Asset | 496.19 M | ||||
| Retained Earnings | (703.43 M) | ||||
| Working Capital | 453.17 M | ||||
| Net Asset | 496.19 M |
About Neumora Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neumora Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neumora Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neumora Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Common Stock:Check out Neumora Therapeutics, Piotroski F Score and Neumora Therapeutics, Altman Z Score analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Return On Assets (0.38) | Return On Equity (0.77) |
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.